Anti-5t4 antibodies and antibody-drug conjugates
AssigneeSynthon Biopharmaceuticals B.V.
InventorsMiranda Maria Cornelia VAN DER LEE, Gerardus Joseph Andreas ARIAANS, Jan SCHOUTEN, Marion BLOMENROHR, Patrick Gerhard GROOTHUIS, Rudy Gerardus Elisabeth COUMANS
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.
Claims19
An anti-5T4 antibody comprising heavy chain (HC) and light chain (LC) variable region (VR) complementarity determining regions (CDRs) selected from the group consisting of:
- a. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:1 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:2;
- b. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:3 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:4;
- c. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:5 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:6;
- d. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:7 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:8;
- e. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:9 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:10;
- f. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:11 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:12;
- g. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:13 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:14;
- h. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:15 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:16;
- i. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:17 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:18;
- j. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:19 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:20;
- k. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:21 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:22;
- l. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:23 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:24;
- m. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:25 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:26;
- n. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:27 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:28;
- o. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:29 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:30;
- p. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:31 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:32;
- and
- q. CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:33 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:34.
(canceled)
Dependencies are inferred from the claim text.